Pramlintide Diabetes Review Could Give Amylin Inroad To Obesity Market
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's lengthy review of Amylin's pramlintide for diabetes may help to position the drug for an obesity indication by clarifying the synthetic amylin analogue's effect on weight